ConductScience.org, home

Paper28036044

Immuno-PET for Clinical Theranostic Approaches.

Bailly C and 10 others. Int J Mol Sci, 2016. Cited by 55 papers, by iCite.

Cite this record

ConductScience Library. Immuno-PET for Clinical Theranostic Approaches. Papers, record 28036044. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28036044

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Immuno-PET for Clinical Theranostic Approaches.
PubMed
Journal
Int J Mol Sci
PubMed
Year
2016
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
55
iCite
Relative citation ratio, by iCite
1.98
iCite
Revised in PubMed
2018-11-13
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bailly CClément
2Cléry PFPierre-François
3Faivre-Chauvet AAlain
4Bourgeois MMickael
5Guérard FFrançois
6Haddad FFerid
7Barbet JJacques
8Chérel MMichel
9Kraeber-Bodéré FFrançoise
10Carlier TThomas
11Bodet-Milin CCaroline

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, MonoclonalMajor topic
NeoplasmsMajor topic
Positron-Emission TomographyMajor topic
RadiopharmaceuticalsMajor topic
Animals
Humans

References80

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
123495938Nanobodies: natural single-domain antibodies.Annu Rev Biochem2013https://conductscience.org/library/papers/23495938PubMed
219596702Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.Ann Oncol2009https://conductscience.org/library/papers/19596702PubMed
316187937Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges.Expert Opin Biol Ther2005https://conductscience.org/library/papers/16187937PubMed
424859229Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer.MAbs2014https://conductscience.org/library/papers/24859229PubMed
517921028Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.Nucl Med Biol2007https://conductscience.org/library/papers/17921028PubMed
616585157Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.Cancer Res2006https://conductscience.org/library/papers/16585157PubMed
725143071⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.Eur J Nucl Med Mol Imaging2014https://conductscience.org/library/papers/25143071PubMed
811722986Immunotherapy of Non-Hodgkin's lymphomas.Hematology Am Soc Hematol Educ Program2001https://conductscience.org/library/papers/11722986PubMed
914988743Monoclonal antibodies in human cancer.Drugs Today (Barc)2003https://conductscience.org/library/papers/14988743PubMed
1027230928
Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial.
J Nucl Med2016https://conductscience.org/library/papers/27230928PubMed
1124643780Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer.Eur J Nucl Med Mol Imaging2014https://conductscience.org/library/papers/24643780PubMed
1223908265Designing the magic bullet? The advancement of immuno-PET into clinical use.J Nucl Med2013https://conductscience.org/library/papers/23908265PubMed
1319443594A novel method of 18F radiolabeling for PET.J Nucl Med2009https://conductscience.org/library/papers/19443594PubMed
1425647074Radiopharmaceuticals as probes to characterize tumour tissue.Eur J Nucl Med Mol Imaging2015https://conductscience.org/library/papers/25647074PubMed
1516530813Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance.Acta Histochem2006https://conductscience.org/library/papers/16530813PubMed
169831223ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients.Prostate1998https://conductscience.org/library/papers/9831223PubMed
1716611412The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.Neoplasia2006https://conductscience.org/library/papers/16611412PubMed
1823213092Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial.J Clin Oncol2013https://conductscience.org/library/papers/23213092PubMed
1925216864Discordances in ER, PR and HER2 receptors between primary and recurrent/metastatic lesions and their impact on survival in breast cancer patients.Med Oncol2014https://conductscience.org/library/papers/25216864PubMed
2023590171PET imaging in prostate cancer: focus on prostate-specific membrane antigen.Curr Top Med Chem2013https://conductscience.org/library/papers/23590171PubMed

See all 80 referencesDownload CSV of references

Cited by44

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 55 citations.

PMIDTitleJournalYearIn PapersSource
42588729Predicting Therapeutic Response to Antibody-Drug Conjugates Using Targeted PET Imaging: A Systematic Review.Cancers (Basel)2026https://conductscience.org/library/papers/42588729PubMed
42540187Development and Preclinical Evaluation of a Novel EpCAM-Targeted 111In-Labeled Antibody for SPECT Imaging.ACS Omega2026https://conductscience.org/library/papers/42540187PubMed
41469159Construction and Evaluation of Guanylyl Cyclase C-Specific Antibody for Noninvasive Diagnosis and Targeted Therapy of Colorectal Cancer.J Nucl Med2026https://conductscience.org/library/papers/41469159PubMed
40459707Augmentation of [18F]-C-SNAT4 PET imaging of apoptosis after radiotherapy using a cold mixing strategy.EJNMMI Res2025https://conductscience.org/library/papers/40459707PubMed
39858014Nuclear Medicine and Molecular Imaging in Urothelial Cancer: Current Status and Future Directions.Cancers (Basel)2025https://conductscience.org/library/papers/39858014PubMed
39540283Emerging Imaging Techniques for Atherosclerosis in Systemic Immune-Mediated Inflammatory Conditions.Arterioscler Thromb Vasc Biol2025https://conductscience.org/library/papers/39540283PubMed
39355220Advances and challenges in immunoPET methodology.Front Nucl Med2024https://conductscience.org/library/papers/39355220PubMed
39192059Development of 52Mn Labeled Trastuzumab for Extended Time Point PET Imaging of HER2.Mol Imaging Biol2024https://conductscience.org/library/papers/39192059PubMed
39065579Zirconium 89 and Copper 64 for ImmunoPET: From Antibody Bioconjugation and Radiolabeling to Molecular Imaging.Pharmaceutics2024https://conductscience.org/library/papers/39065579PubMed
38665417In Vivo Detection of Staphylococcus aureus Infections Using Radiolabeled Antibodies Specific for Bacterial Toxins.Int J Biomed Imaging2024https://conductscience.org/library/papers/38665417PubMed
37895958Development and Preclinical Evaluation of [68Ga]BMSH as a New Potent Positron Emission Tomography Tracer for Imaging Programmed Death-Ligand 1 Expression.Pharmaceuticals (Basel)2023https://conductscience.org/library/papers/37895958PubMed
37752092Application of interim PET-CT in first-line treatment decision-making for lymphoma.J Zhejiang Univ Sci B2023https://conductscience.org/library/papers/37752092PubMed
37298101Recent Advances in 64Cu/67Cu-Based Radiopharmaceuticals.Int J Mol Sci2023https://conductscience.org/library/papers/37298101PubMed
37027345Dual-Peak Lorentzian CEST MRI for antiretroviral drug brain distribution.NeuroImmune Pharm Ther2023https://conductscience.org/library/papers/37027345PubMed
36591250Cysteine-specific 89Zr-labeled anti-CD25 IgG allows immuno-PET imaging of interleukin-2 receptor-α on T cell lymphomas.Front Immunol2022https://conductscience.org/library/papers/36591250PubMed
35393508Imaging immunity in patients with cancer using positron emission tomography.NPJ Precis Oncol2022https://conductscience.org/library/papers/35393508PubMed
35309962Development of Dual Receptor Enhanced Pre-Targeting Strategy-A Novel Promising Technology for Immuno-Positron Emission Tomography Imaging.Adv Ther (Weinh)2021https://conductscience.org/library/papers/35309962PubMed
34621145Preclinical Molecular PET-CT Imaging Targeting CDCP1 in Colorectal Cancer.Contrast Media Mol Imaging2021https://conductscience.org/library/papers/34621145PubMed
34361793IEDDA: An Attractive Bioorthogonal Reaction for Biomedical Applications.Molecules2021https://conductscience.org/library/papers/34361793PubMed
34026426CD38-Targeted Theranostics of Lymphoma with 89Zr/177Lu-Labeled Daratumumab.Adv Sci (Weinh)2021https://conductscience.org/library/papers/34026426PubMed

See all 44 cited byDownload CSV of cited by

Genes9

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28036044

GET https://conductscience.org/api/papers/v1/28036044/references?page=2